These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36908985)

  • 21. Optimized Therapeutic
    Wu Y; Zhang X; Duan X; Yang X; Wang F; Zhang J
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36558981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
    Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
    J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer.
    Sun M; Niaz MJ; Niaz MO; Tagawa ST
    Curr Oncol Rep; 2021 Mar; 23(5):59. PubMed ID: 33778927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
    Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and Evaluation of
    Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
    Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
    Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
    J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
    Zha Z; Choi SR; Li L; Zhao R; Ploessl K; Yao X; Alexoff D; Zhu L; Kung HF
    J Med Chem; 2022 Oct; 65(19):13001-13012. PubMed ID: 36103652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.
    Weineisen M; Simecek J; Schottelius M; Schwaiger M; Wester HJ
    EJNMMI Res; 2014 Dec; 4(1):63. PubMed ID: 26116124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin.
    Reissig F; Zarschler K; Novy Z; Petrik M; Bendova K; Kurfurstova D; Bouchal J; Ludik MC; Brandt F; Kopka K; Khoylou M; Pietzsch HJ; Hajduch M; Mamat C
    Theranostics; 2022; 12(17):7203-7215. PubMed ID: 36438496
    [No Abstract]   [Full Text] [Related]  

  • 31. Synthesis and Preclinical Evaluation of
    Wurzer A; Kunert JP; Fischer S; Felber V; Beck R; Rose F; D'Alessandria C; Weber W; Wester HJ
    J Nucl Med; 2022 Oct; 63(10):1489-1495. PubMed ID: 35086894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep.
    Baur B; Solbach C; Andreolli E; Winter G; Machulla HJ; Reske SN
    Pharmaceuticals (Basel); 2014 Apr; 7(5):517-29. PubMed ID: 24787458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer.
    Sengupta S; Krishnan MA; Dudhe P; Reddy RB; Giri B; Chattopadhyay S; Chelvam V
    Beilstein J Org Chem; 2018; 14():2665-2679. PubMed ID: 30410628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved quality control of [
    Kraihammer M; Garnuszek P; Bauman A; Maurin M; Alejandre Lafont M; Haubner R; von Guggenberg E; Gabriel M; Decristoforo C
    EJNMMI Radiopharm Chem; 2023 Mar; 8(1):7. PubMed ID: 36971890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer.
    Eder M; Schäfer M; Bauder-Wüst U; Haberkorn U; Eisenhut M; Kopka K
    Prostate; 2014 May; 74(6):659-68. PubMed ID: 24464532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving the Imaging Contrast of
    Baranski AC; Schäfer M; Bauder-Wüst U; Wacker A; Schmidt J; Liolios C; Mier W; Haberkorn U; Eisenhut M; Kopka K; Eder M
    Bioconjug Chem; 2017 Sep; 28(9):2485-2492. PubMed ID: 28787147
    [No Abstract]   [Full Text] [Related]  

  • 37. Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
    Felber VB; Valentin MA; Wester HJ
    EJNMMI Radiopharm Chem; 2021 Feb; 6(1):10. PubMed ID: 33638060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
    J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.
    Lahnif H; Grus T; Pektor S; Greifenstein L; Schreckenberger M; Rösch F
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.